SGMO News and Press, Sangamo Therapeutics Inc. From 11/04/21

Sangamo Therapeutics, Inc. (SGMO) Q3 2021 Earnings Conference Call November 4, 2021 9:15 AM ET Company Participants Aron Feingold – Head-Corporate Communications Sandy Macrae – Chief Executive Officer Prathyusha Duraibabu – Chief Financial Officer Bettina Cockroft –...

Shares of Sangamo Therapeutics (SGMO +21.6%) are up 22% after the company released Q3 2021 earnings that beat estimates and posted an update on a phase 1 Fabry disease program. Year over year, revenue in the quarter declined 51% to $28.6M. This was primarily due to a $39.3M decrease related t...

Sangamo Therapeutics' (SGMO +21.4%) isaralgagene civaparvovec (ST-920) for Fabry disease was well tolerated in a phase 1/2 trial. In addition, the four patients in the trial all exhibited fabove normal alpha-galactosidase A (α-Gal A) activity. No treatment-related adverse events h...

Sangamo Therapeutics (NASDAQ:SGMO): GAAP EPS of -$0.33 beats by $0.01. Revenue of $28.6M beats by $2.64M. Cash, cash equivalents and marketable securities as of September 30, 2021 were $519M compared to $692M as of December 31, 2020. Press Release For further details see: Sangamo Therap...

Conference Call and Webcast Scheduled for 9:15 a.m. Eastern Time Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported third quarter financial results and provided business and clinical highlights. “We are delighted to share clinica...

- Preliminary data showed that isaralgagene civaparvovec, or ST-920, was generally well tolerated - All four patients in the first two dose cohorts exhibited above normal α-Gal A activity, which was maintained for up to one year for the first patient treated - Based...

ABC, ABUS, ACIW, ADAP, AES, AHCO, AKBA, ALBO, ALE, APD, APTV, ARW, ASPS, ATNX, ATRA, ATRS, BCE, BDX, BLDR, BLI, BLL, BRG, BXRX, CARS, CCOI, CFX, CHH, CI, CLDT, CMRX, CNHI, CNP, CNQ, COMM, CPE, CS, CTXS, CWEN, CYBR, DBRG, DEN, DIN, DISH, DLX, DNB, DOCN, DUK, EPAM, ERJ, ESTE, EURN, EVA, FIS, FW...

Sangamo Therapeutics (NASDAQ:SGMO) is scheduled to announce Q3 earnings results on Thursday, November 4th, before market open. The consensus EPS Estimate is -$0.33 and the consensus Revenue Estimate is $25.96M (-55.1% Y/Y). The company had reported second-quarter revenue that beat Wall Street...

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its third quarter 2021 financial results on Thursday, November 4, 2021. The press release will be followed by a conference call at 9:15 a.m. ET, which wil...

MaxCyte has become the go-to partner for biotech companies using non-viral cell engineering, aided by its proprietary patented flow electroporation technology. The company has a scalable (licenses and SPLs) business model with recurring revenues. Milestone and royalty payments (at 100...